53
Participants
Start Date
September 18, 2017
Primary Completion Date
September 14, 2023
Study Completion Date
September 14, 2023
Pomalidomide
: Subjects will be administered pomalidomide on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle and will continue treatment for up to 24 cycles or until disease progression, withdrawal of consent/assent or unresolved toxicities as described in the protocol.
Pomalidomide
Pomalidomide will be provided as gelatin capsules and as an oral suspension. The starting dose will be 2.6 mg/m²/day, administered on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle.
Local Institution - 201, Genova
Local Institution - 302, Barcelona
Local Institution - 103, Marseille
Local Institution - 200, Milan
Local Institution - 506, Bethesda
Local Institution - 300, Madrid
Local Institution - 106, Toulouse
University Of Florida, Gainesville
Local Institution - 301, Valencia
Local Institution - 105, Vandœuvre-lès-Nancy
Local Institution - 104, Lille
Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago
Local Institution - 102, Lyon
Local Institution - 100, Paris
Texas Children's Hospital, Houston
Local Institution - 101, Villejuif
Stanford University Cancer Center, Stanford
Dana Farber Cancer Institute, Boston
Local Institution - 202, Roma
Local Institution - 400, Leeds
Local Institution - 403, London
Local Institution - 401, Sutton-Surrey
Lead Sponsor
Celgene
INDUSTRY